409 related articles for article (PubMed ID: 26186678)
1. ADAMTS13 and von Willebrand factor interactions.
Zander CB; Cao W; Zheng XL
Curr Opin Hematol; 2015 Sep; 22(5):452-9. PubMed ID: 26186678
[TBL] [Abstract][Full Text] [Related]
2. Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies.
Soejima K; Nakagaki T
Semin Hematol; 2005 Jan; 42(1):56-62. PubMed ID: 15662617
[TBL] [Abstract][Full Text] [Related]
3. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
Luken BM; Turenhout EA; Hulstein JJ; Van Mourik JA; Fijnheer R; Voorberg J
Thromb Haemost; 2005 Feb; 93(2):267-74. PubMed ID: 15711742
[TBL] [Abstract][Full Text] [Related]
4. [ADAMTS13-Mediated Proteolytic Cleavage of Unusually Large von Willebrand Factor Polymers on Endothelial Cells in the Absence of Fluid Shear Stress].
Zhao SC; Li H; Wang M; Zhao YH; Li XJ; Jin SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):532-540. PubMed ID: 38660863
[TBL] [Abstract][Full Text] [Related]
5. Conformational activation of ADAMTS13.
South K; Luken BM; Crawley JT; Phillips R; Thomas M; Collins RF; Deforche L; Vanhoorelbeke K; Lane DA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18578-83. PubMed ID: 25512499
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Jian C; Xiao J; Gong L; Skipwith CG; Jin SY; Kwaan HC; Zheng XL
Blood; 2012 Apr; 119(16):3836-43. PubMed ID: 22289888
[TBL] [Abstract][Full Text] [Related]
8. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.
Pos W; Crawley JT; Fijnheer R; Voorberg J; Lane DA; Luken BM
Blood; 2010 Feb; 115(8):1640-9. PubMed ID: 20032502
[TBL] [Abstract][Full Text] [Related]
9. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
Casina VC; Hu W; Mao JH; Lu RN; Hanby HA; Pickens B; Kan ZY; Lim WK; Mayne L; Ostertag EM; Kacir S; Siegel DL; Englander SW; Zheng XL
Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9620-5. PubMed ID: 26203127
[TBL] [Abstract][Full Text] [Related]
10. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
11. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
Zheng X; Nishio K; Majerus EM; Sadler JE
J Biol Chem; 2003 Aug; 278(32):30136-41. PubMed ID: 12791682
[TBL] [Abstract][Full Text] [Related]
12. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
Matsumoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429
[TBL] [Abstract][Full Text] [Related]
13. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Shelat SG; Ai J; Zheng XL
Semin Thromb Hemost; 2005 Dec; 31(6):659-72. PubMed ID: 16388417
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.
Soejima K; Matsumoto M; Kokame K; Yagi H; Ishizashi H; Maeda H; Nozaki C; Miyata T; Fujimura Y; Nakagaki T
Blood; 2003 Nov; 102(9):3232-7. PubMed ID: 12869506
[TBL] [Abstract][Full Text] [Related]
15. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
Halkidis K; Zheng XL
J Thromb Haemost; 2022 Oct; 20(10):2197-2203. PubMed ID: 35842925
[TBL] [Abstract][Full Text] [Related]
16. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
Thomas MR; de Groot R; Scully MA; Crawley JT
EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
[TBL] [Abstract][Full Text] [Related]
17. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Tsai HM
J Mol Med (Berl); 2002 Oct; 80(10):639-47. PubMed ID: 12395148
[TBL] [Abstract][Full Text] [Related]
19. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.
Jin SY; Skipwith CG; Zheng XL
Blood; 2010 Mar; 115(11):2300-10. PubMed ID: 20075158
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
